ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

URGN UroGen Pharma Ltd

14.21
-0.32 (-2.20%)
Apr 24 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 97,025
Bid Price 14.21
Ask Price 19.53
News -
Day High 14.758

Low
8.69

52 Week Range

High
24.13

Day Low 14.19
Company Name Stock Ticker Symbol Market Type
UroGen Pharma Ltd URGN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.32 -2.20% 14.21 20:00:00
Open Price Low Price High Price Close Price Prev Close
14.66 14.19 14.758 14.21 14.53
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,895 97,025 $ 14.43 $ 1,400,081 - 8.69 - 24.13
Last Trade Time Type Quantity Stock Price Currency
16:02:23 priorref 510 $ 14.21 USD

UroGen Pharma Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
484.87M 34.12M - 82.71M -102.24M -3.00 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

UroGen Pharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No URGN Message Board. Create One! See More Posts on URGN Message Board See More Message Board Posts

Historical URGN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week14.6114.8513.1714.17277,513-0.40-2.74%
1 Month15.5915.669912.3714.33314,919-1.38-8.85%
3 Months15.8419.8712.3716.24377,578-1.63-10.29%
6 Months11.2519.8710.6315.13317,5172.9626.31%
1 Year9.8924.138.6916.09382,4584.3243.68%
3 Years19.6124.134.8514.05205,888-5.40-27.54%
5 Years38.0439.974.8518.56199,281-23.83-62.64%

UroGen Pharma Description

UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy.

Your Recent History

Delayed Upgrade Clock